Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Editas Medicine (EDIT) Receivables (2016 - 2025)

Historic Receivables for Editas Medicine (EDIT) over the last 11 years, with Q3 2025 value amounting to $8.1 million.

  • Editas Medicine's Receivables rose 635238.1% to $8.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $8.1 million, marking a year-over-year increase of 635238.1%. This contributed to the annual value of $16.3 million for FY2024, which is 5967.41% up from last year.
  • Latest data reveals that Editas Medicine reported Receivables of $8.1 million as of Q3 2025, which was up 635238.1% from $588000.0 recorded in Q2 2025.
  • Editas Medicine's 5-year Receivables high stood at $16.3 million for Q4 2024, and its period low was $120000.0 during Q3 2022.
  • Moreover, its 5-year median value for Receivables was $588000.0 (2025), whereas its average is $2.6 million.
  • As far as peak fluctuations go, Editas Medicine's Receivables crashed by 9558.53% in 2021, and later soared by 635238.1% in 2025.
  • Quarter analysis of 5 years shows Editas Medicine's Receivables stood at $267000.0 in 2021, then surged by 1826.97% to $5.1 million in 2022, then skyrocketed by 98.0% to $10.2 million in 2023, then surged by 59.67% to $16.3 million in 2024, then tumbled by 50.02% to $8.1 million in 2025.
  • Its Receivables stands at $8.1 million for Q3 2025, versus $588000.0 for Q2 2025 and $510000.0 for Q1 2025.